The Bombay High Court criticized the Maharashtra FDA for its drastic actions against companies. The court directed the regulator to grant hearings before taking severe measures. This directive came after Cadila Pharmaceuticals challenged the FDA's drug seizure and sales ban. The FDA agreed to revoke orders and provide hearings to the petitioner. The court warned of imposing heavy costs on the FDA for its actions.
